Capitalising on the Unique Value of Medical Affairs
Pharmaceutical companies face complex challenges that the Medical Affairs function is uniquely positioned to help overcome. Specifically, Medical Affairs can support pharma in three key areas: In this white paper, we examine how the unique value of Medical Affairs can be successfully leveraged, with an emphasis on: Pharma companies should capitalise on the unique value […]
What MidPharmas Should do about Artificial Intelligence in Drug Discovery
Artificial Intelligence (AI) has the potential to transform and significantly accelerate drug discovery, and so its integration has become a pivotal focus for pharmaceutical companies. However, the scale and heritage of MidPharmas make it challenging to adapt to emerging technologies. They have limited financial and human resources, making acquisitions riskier and the integration of technology […]
Maximise Biotech Value Creation
Biotech companies face unique challenges in creating value and securing investment. To succeed, they must be strategically and operationally excellent. To move quickly to the next value inflection point, biotech companies must have a compelling strategic focus, clear asset prioritisation, and a fit-for-purpose operating model. In this white paper, we focus on the key imperatives […]
The Novasecta European MidPharma Report 2023
Europe is home to 93 ‘MidPharmas’: companies with €100m-€10bn annual revenue that develop and commercialise pharmaceutical products. In our eighth annual European MidPharma report, we examine this important sector of the pharmaceutical industry and contrast it with European-headquartered Big Pharma. We also take a closer look at the ingredients required for continued success. What to […]
Overcoming Pharma’s Value and Access Challenges
As healthcare budgets continue to tighten, the pharmaceutical industry is becoming increasingly crowded with innovative, expensive medicines. Demonstrating the value of new medicines and negotiating a price that rewards investment in innovation is becoming increasingly challenging for pharma companies. Payers are evolving value assessment approaches and pricing policy to manage the challenge of reimbursing new […]
How Pharma Manages Organisational Complexity (MedNous)
Big Pharma companies deliver value and innovation to patients through the scale and diversity of their portfolios. However, as scale and diversity increase, so too does organisational complexity. To effectively manage increasing complexity, organisations need to define a clear strategic focus and embed a fit-for-purpose operating model. This article, published in MedNous, analyses six companies […]
Approaches to Managing Organisational Complexity
Big Pharma companies deliver value and innovation to patients through the scale and diversity of their portfolios. However, as scale and diversity increase, so too does organisational complexity. To effectively manage increasing complexity, organisations need to define a clear strategic focus and embed a fit-for-purpose operating model. There is no single approach to doing this, […]
Managing Organisational Complexity in Big Pharma
Organisational complexity and scale are two sides of the same coin. In a quest for scale, Big Pharma companies have built large, diverse portfolios that span multiple therapeutic areas and technologies. But this comes with its own set of challenges. Portfolio diversity leads to inevitable organisational complexity, requiring leaders to think more proactively about decision-making […]
The Art of Effective R&D Transformation
An effective pharmaceutical R&D transformation shapes the R&D function into a high-performing one. Such transformations cover many aspects and affect many people, so require clarity, simplicity, and sustained effort to have an impact. The reason that companies engage in R&D transformation is usually a concern about R&D productivity. High attrition rates and regulations that increase […]
Transform Value And Access
A complex and evolving pharmaceutical ecosystem driven by rapidly changing healthcare policies, increasing payer sophistication, and greater patient needs, makes a challenging environment in which to secure favourable patient access to medicines. Patient access will be at the top of the leadership agenda for pharmaceutical companies. To deliver it will require the transformation of Value […]